검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Trastuzumab Emtansine) Roche / Genentech·Metastatic Salivary Gland Carcinom… ORR 69.3%·t½ 4 h | |
|---|---|---|
Overview Program | Trastuzumab Emtansine | Abemaciclib |
Overview Company | Roche / Genentech | Eli Lilly and Company |
Overview Modality | ADC | ADC |
Overview Target | Metastatic Salivary Gland Carcinoma | HER2 |
Overview Indication | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer | Advanced Cancer; Metastatic Melanoma |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targeting human epidermal growth factor receptor | Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) |
MoA Biomarker | HER2-positive | biomarkers |
PK/PD Half-life | 4 h | 18.3 h |
PK/PD Species | Mouse | Mouse, xenograft, local recurrences, and distant metastases demonstrat |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition | pharmacokinetic |
Toxicology Species | Mouse, Rat | Dog, Mouse, Rat, Hamster, xenograft, local recurrences, and distant metastases demonstrat |
Toxicology Animal (cat.) | Rat | Mouse, Rat, Dog |
Toxicology Major finding | Hepatotoxicity Hepatotoxicity, predominantly in the form of asymptomatic, transient increas | Hepatotoxicity: Increases in serum transaminase levels have been observed |
Clinical Primary efficacy | ORR 69.3% | ORR 32.9% |
Clinical ORR | 69.3% | 32.9% |
Clinical Result source | ClinicalTrials.gov NCT01120184 | ClinicalTrials.gov NCT02675231 |
Clinical Data Tier / Score | S · 66 | C · 46 |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (10일 전) | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab (Herceptin, Trastuzumab Emtansine) Roche / Genentech·Metastatic Salivary Gland Carcinom… ORR 69.3%·t½ 4 h | |
|---|---|---|
Overview Program | Trastuzumab Emtansine | Abemaciclib |
Overview Company | Roche / Genentech | Eli Lilly and Company |
Overview Modality | ADC | ADC |
Overview Target | Metastatic Salivary Gland Carcinoma | HER2 |
Overview Indication | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer | Advanced Cancer; Metastatic Melanoma |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | RECRUITING | RECRUITING |
MoA Mechanism | targeting human epidermal growth factor receptor | Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) |
MoA Biomarker | HER2-positive | biomarkers |
PK/PD Half-life | 4 h | 18.3 h |
PK/PD Species | Mouse | Mouse, xenograft, local recurrences, and distant metastases demonstrat |
PK/PD Animal (cat.) | Mouse, In vitro | Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition | pharmacokinetic |
Toxicology Species | Mouse, Rat | Dog, Mouse, Rat, Hamster, xenograft, local recurrences, and distant metastases demonstrat |
Toxicology Animal (cat.) | Rat | Mouse, Rat, Dog |
Toxicology Major finding | Hepatotoxicity Hepatotoxicity, predominantly in the form of asymptomatic, transient increas | Hepatotoxicity: Increases in serum transaminase levels have been observed |
Clinical Primary efficacy | ORR 69.3% | ORR 32.9% |
Clinical ORR | 69.3% | 32.9% |
Clinical Result source | ClinicalTrials.gov NCT01120184 | ClinicalTrials.gov NCT02675231 |
Clinical Data Tier / Score | S · 66 | C · 46 |
Clinical Program phase | APPROVED | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (10일 전) | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교